Ultragenyx Pharmaceutical (RARE) EBT Growth (5y) (2018 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Ultragenyx Pharmaceutical | 2.29 Bn | 1.89 Bn | 106.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -6.27% |
| Dec 31, 2025 | -39.77% |
| Sep 30, 2025 | -21.24% |
| Jun 30, 2025 | -45.10% |
| Mar 31, 2025 | -4.81% |
| Dec 31, 2024 | 46.35% |
| Sep 30, 2024 | -3.40% |
| Jun 30, 2024 | -5.73% |
| Mar 31, 2024 | -12.01% |
| Dec 31, 2023 | -7.76% |
| Sep 30, 2023 | -12.80% |
| Jun 30, 2023 | -24.76% |
| Mar 31, 2023 | -49.21% |
| Dec 31, 2022 | -9.37% |
| Sep 30, 2022 | -24.69% |
| Jun 30, 2022 | -16.72% |
| Mar 31, 2022 | -17.32% |
| Dec 31, 2021 | -11.86% |
| Sep 30, 2021 | -2.33% |
| Jun 30, 2021 | -16.46% |
| Mar 31, 2021 | -20.86% |
| Dec 31, 2020 | 15.40% |
| Sep 30, 2020 | -11.78% |
| Jun 30, 2020 | 23.45% |
| Mar 31, 2020 | -41.07% |
| Dec 31, 2019 | -40.36% |
| Sep 30, 2019 | -48.39% |
| Jun 30, 2019 | -48.76% |
| Mar 31, 2019 | -47.93% |
| Dec 31, 2018 | -56.09% |
| Sep 30, 2018 | -62.46% |
| Jun 30, 2018 | -43.49% |
| Mar 31, 2018 | 45.32% |